Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

Diabetes, Obesity and Metabolism

Volumn 10, Issue 11, 2008, Pages 1114-1124

  Scherbaum, W A ^a   Schweizer, A ^b   Mari, A ^c   Nilsson, P M ^d   Lalanne, G ^e   Wang, Y ^b   Dunning, B E ^f   Foley, James E ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CNR   (Italy)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e Medical Group   (France)

^f PharmaWrite LLC   (United States)

Author keywords

Adverse events; Fasting plasma glucose; Type 2 diabetes; Vildagliptin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; VILDAGLIPTIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CERVICOBRACHIAL NEURALGIA; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EVIDENCE BASED MEDICINE; FEMALE; GASTRITIS; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN RELEASE; ISCHIALGIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SPRAIN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 53549129604     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00875.x     Document Type: Article

References (23)

1. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138.
2. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
3. 1c over one year in drug-naïve patients with type 2 diabetes. Diabet Med 2007; 24: 955-961.
4. Mari A, Scherbaum WA, Nilsson PM et al. Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008; 93: 103-109.
5. Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia. Diabetes Obes Metab doi: 10.1111/j.1463-1326.2008.00850.
6. van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
7. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-893.
8. Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 (T2DM) and mild hyperglycemia. Diabetes 2007; 55: A134.
9. Rosenstock J, Foley JE, Rendell M et al. Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-35.
10. Utzschneider KM, Tong J, Montgomery B et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves {beta}-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008; 31: 108-113.
11. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 175-185.
12. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539-548.
13. Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: Role of potentiation. Diabetes 2002; 51 (Suppl. 1): S221-S226.
14. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002; 283: E1159-E1166.
15. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006; 57: 265-281.
16. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423-428.
17. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-698.
18. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
19. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 218-223.
20. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.
21. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166-174.
22. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Care 2007; 30: 217-223.
23. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 82-90.